WO2012163792A1 - Nouveaux antagonistes de p2x7r et leur utilisation - Google Patents

Nouveaux antagonistes de p2x7r et leur utilisation Download PDF

Info

Publication number
WO2012163792A1
WO2012163792A1 PCT/EP2012/059693 EP2012059693W WO2012163792A1 WO 2012163792 A1 WO2012163792 A1 WO 2012163792A1 EP 2012059693 W EP2012059693 W EP 2012059693W WO 2012163792 A1 WO2012163792 A1 WO 2012163792A1
Authority
WO
WIPO (PCT)
Prior art keywords
indole
carboxamide
hydroxyoxetan
methyl
ethyl
Prior art date
Application number
PCT/EP2012/059693
Other languages
English (en)
Inventor
Michael Boes
Original Assignee
Affectis Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affectis Pharmaceuticals Ag filed Critical Affectis Pharmaceuticals Ag
Publication of WO2012163792A1 publication Critical patent/WO2012163792A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present application relates to novel P2X7R antagonists that are indol-3 carboxamide and azaindol-3 carboxamide compounds, pharmaceutical compositions comprising these compounds and to their use in the prophylactic and therapeutic treatment of diseases and disorders mediated by P2X7R.
  • P2X7R is an ATP-gated ion channel belonging to the P2X ionotropic channel family.
  • the gene was first isolated from rat brain (Surprenant et al. (1996) 272:735-738) and subsequently from a human monocyte library (Rassendren et al. (1997) J. Biol. Chem. 272:5482-5486; Genbank accession numbers NM_002562, Y09561 ) by virtue of its sequence homology with the other members of the P2X family.
  • P2X7R corresponded to the unidentified P2Z receptor which mediates the permeabilising action of ATP on mast cells and macrophages (Dahlqvist and Diamant (1974) Acta Physiol. Scand. 34:368-384; Steinberg and Silverstein (1987) J. Biol. Chem. 262:31 18-3122; Gordon (1986) Biochem. J. 233:309-319).
  • the P2X7R has two hydrophobic membrane-spanning domains, an extracellular loop, and forms transmembrane ion channels.
  • P2X7R bears a pharmacological profile markedly different from other P2X homo- or heteromers (North and Surprenant (2000) Annual Rev.
  • P2X7R is expressed in haematopoietic cells, mast cells, lymphocytes, erythrocytes, fibroblast, Langerhans cells, and macrophages (Surprenant et al., 1996, Science 272:31 18-3122).
  • P2X7R expression has been reported in glial cells, Schwann cells, astrocytes, as well as in neurons (Ferrari et al. (1996) J. Immunol 156:1531-1539; Collo et al. (1997) Neuropharmacology 36: 1277- 1283; Anderson and Nedergaard (2006) Trends Neuroscien 29: 257-262).
  • P2X7R is involved in the regulation of the immune function and inflammatory response. Activation of P2X7R by ATP in macrophages is associated with mitogenic stimulation of T cells (Baricordi et al. (1996) Blood 87:682-690), the release of cytokines (Griffiths et al. (1995) J. Immol. 154:2821-2828), and formation of macrophage polykarions (Falzoni et al. (1995) J. Clin. Invest. 95:1207-1216).
  • P2X7R is involved in the processing and release of active interleukin-1 beta (I L-1 ⁇ ) from proinflammatory cells (Perregaux and Gabel (1998) J Biol Chem 269:15195-15203; Ferrari et al., (2006) J Immunol 176: 3877-3883). Stimulation of the P2X7R by ATP can also result in apoptosis and cell death by triggering the formation of non-selective plasma membrane pores (Di Virgilio et a!. (1998) Cell Death Differ. 5:191 -199).
  • P2X7R Upregulation of P2X7R has been observed during ischemic damage and necrosis induced by occlusion of middle cerebral artery in rat brain (Collo et al. (1997) Neuropharmacol 36:1277-1283). Recent studies indicate a role of P2X7R in the generation of superoxide in microglia, and upregulation of P2X7R has been detected around amyloid plaques in a transgenic mouse models for Alzheimer's disease (Parvathenani et al. (2003) J Biol Chem 278:13300-13317) and in multiple sclerosis lesions from autopsy brain sections (Narcisse et al. (2005) Glia, 49:245-258). Inhibition of P2X7 can improve symptoms in a model of multiple sclerosis (Matute et al. (2007) J Neurosci 27:9525-9533).
  • mice lacking P2X7R resulted in absence of inflammatory and neuropathic hypersensitivity to mechanical and thermal stimuli, indicating a link between P2X7R and inflammatory and neuropathic pain (Chessell et al. (2005) Pain 1 14:386-396).
  • Antagonists of P2X7R significantly improved functional recovery and decreased cell death in spinal cord injury in animal models (Wang et al. (2004) Nature Med 10:B21 -B27).
  • P2X7 has also been shown to be involved in depression and anxiety (Basso et al. (2009) Behav Brain Res 198:83-90; WO 2009/019503); bipolar affective disorders (Barden et al.
  • adamantane derivatives WO 99/29660, WO 99/29661 , WO 00/61569, WO 01/42194, WO 01/44170, WO 01/44213, WO 01/94338, WO 03/041707, WO 03/042190, WO 03/080579, WO 04/074224, WO 05/014529, WO 06/025783, WO 06/059945), piperidine and piperazine compounds (WO 01/44213, WO 01/46200, WO 08/005368; WO 2010/125103), benzamide and heteroarylamide compounds (WO 03/042191 , WO 04/058731 , WO 04/058270, WO 04/099146, WO 05/019182, WO 06/003500, WO 06/003513, WO 06/067444), substituted tyrosine derivatives (WO 00/71529,
  • the object on the present invention is to provide a novel series of compound which can inhibit P2X7R activity and can be used in the treatment of the above- mentioned diseases.
  • the present invention relates to novel P2X7R antagonists that are lndol-3 carboxamide and azaindol-3 carboxamide compounds represented by the general formula (I):
  • Ri is a mono- or bicycioaikylaikyl group
  • R 2 is selected from hydrogen, -OH, -NH2, or halogen (i.e., CI, F, Br or i);
  • R.3, R 4 , R5, Re are at each occurrence independently selected from hydrogen, halogen (i.e. CI, F, Br or I), d-Ce alkyl, hydroxy, C1-C6 alkoxy, cyano, or trifluoromethyl; n equals 1 or 2; a, b, c, d, x are at each occurrence independently selected from carbon, or nitrogen; or a pharmaceutically acceptable salt or solvate thereof (whereby x must have a hydrogen substituent if it is carbon).
  • halogen i.e. CI, F, Br or I
  • d-Ce alkyl hydroxy, C1-C6 alkoxy, cyano, or trifluoromethyl
  • n equals 1 or 2
  • a, b, c, d, x are at each occurrence independently selected from carbon, or nitrogen; or a pharmaceutically acceptable salt or solvate thereof (whereby x must have a hydrogen substituent if it is carbon).
  • R 3 , R 4 , R 5 , R 6 are at each occurrence independently selected from hydrogen, halogen, methyl, hydroxy, methoxy, cyano, or trifluoromethyl.
  • R-i is a group selected from mono- or bicycioaikylaikyl group selected from cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, cycloheptylethyl, bicyclo[2.2.2]octan-1-ylmethyl, bicyclo[2.2.2]octan-1-ylethyl, adamantanyl-methyl, or adamantanyl-ethyl thereof are preferred.
  • R 2 is selected from -OH or fluoride.
  • R 3 , R 4 , R5 and R 6 are hydrogen.
  • R 4 and R 6 are H, wherein R3 and R 5 are defined as above, or R4-R6 are H, wherein R 3 is defined as above, wherein C C 6 alkyl is preferably methyl and C1-C6 alkoxy is preferably methoxy. If necessitated by valency, R 3 -R 6 may also be absent.
  • the invention further relates to a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, being:
  • the present invention also includes isotopically-labelled compounds, which are identical to those recited in Formula (i), but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass 25 number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 3 C, 14 C, 15 N, 18 0, 17 0, 31 P, 32 P, 35 S, 8 F, and 35 CI, respectively.
  • isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically-labelled compounds of Formula (I) of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Examples below, by substituting a readily available isotopically-labelled reagent for a non- isotopically-labelled reagent.
  • Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine and procaine.
  • nontoxic acid addition salts are salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentaneproprionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hernisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulphate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, per
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulphate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the present application is directed to a pharmaceutical composition comprising a compound of Formula (I) of the present invention.
  • composition according to the present invention may further comprise an additional active compound in separate or unit dosage form for simultaneous or sequential administration.
  • the compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine production by such mammal's cells, such as but not limited to monocytes and/or macrophages.
  • the present invention also relates to the treatment of an IL-1 or cytokine mediated condition.
  • an "IL-1 mediated condition” and “cytokine mediated condition” includes, but is not limited to, a disease or disorder selected from the group consisting of arthritis (including psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and acute synovitis), inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, adult respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, allergic reactions, allergic contact hypersensitivity, eczema, contact dermatitis, psoriasis, sunburn, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, bone resorption disease, loosening
  • arthritis including
  • a host reaction comprising administering to said mammal an amount of a compound to Formula (I), effective in treating such a condition.
  • the present invention relates to a pharmaceutical composition for the treatment of an IL-1 mediated condition in a mammal, including a human, comprising an amount of a compound of Formula (I), effective in treating such a condition and a pharmaceutically acceptable carrier.
  • the compounds of the invention are useful for the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis, irritable bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukemia, diabetes, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischemic heart disease, stroke and varicose veins.
  • COPD chronic obstructive pulmonary disease
  • the invention further provides a pharmaceutical composition for treating osteoarthritis which comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • the invention further provides a pharmaceutical composition for effecting immunosuppression (e.g., in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis) which comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • a pharmaceutical composition for effecting immunosuppression e.g., in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis
  • a pharmaceutical composition for effecting immunosuppression e.g., in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis
  • a pharmaceutical composition for effecting immunosuppression e.g., in the treatment of rheumatoid arthritis, irritable bowel disease, atherosclerosis or psoriasis
  • the invention also provides a pharmaceutical composition for treating an obstructive airways disease (e.g. asthma or COPD) which comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • an obstructive airways disease e.g. asthma or COPD
  • a pharmaceutical composition for treating an obstructive airways disease which comprises a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • the present invention yet further provides a pharmaceutical composition for treating a mammal susceptible to or afflicted with conditions that are causally related to abnormal activity of the P2X7 receptor, such as neurodegenerative diseases and disorders including, for example, Parkinson's disease, multiple sclerosis, glaucoma, age-related macular degeneration, uveitis, neuropathic pain, diseases and disorders which are mediated by or result in neuromfiammation such as, for example traumatic brain injury and encephalitis: centrally-mediated neuropsychlatric diseases and disorders such as, for example depression mania, bipolar disease, anxiety, scnizopnrsnia, eaung Qisoraers, sieep aisoraers ano cognition aisoraers, epiiepsy and seizure disorders comprising a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined.
  • neurodegenerative diseases and disorders including, for example, Parkinson's
  • the pharmaceutical composition according to the present invention may be used for the treatment of affective disorders.
  • the affective disorder is selected from depression, anxiety, bipolar disorder and schizophrenia.
  • the pharmaceutical composition according to the present invention is useful for the treatment of neurodegenerative diseases and disorders, diseases and disorders which are mediated by or result in neuroinflammation and centrally-mediated neuropsychiatric diseases and disorders.
  • the pharmaceutical composition according to the present invention may particulary be useful for the treatment of pain, inflammatory processes, and degenerative conditions.
  • the inflammatory process is selected from rheumatoid arthritis, osteoporosis and chronic obstructive pulmonary disease.
  • composition according to the present invention may be used for the treatment of neuropathic pain.
  • Dosage, pharmaceutical preparation and delivery of a compound of Formula (I) for use in accordance with the present invention can be formulated in conventional manner according to methods found in the art, using one or more physiological carriers or excipient, see, for example Ansel et al., "Pharmaceutical Dosage Forms and Drug Delivery Systems", 7th edition, Lippincott Williams & Wilkins Publishers, 1999.
  • the P2X7R modulating agent and its physiologically acceptable salts and solvates can be formulated for administration by inhalation, insufflation (either through the mouth, or nose), oral, buccal, parenteral, or rectal administration.
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone, hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystailine cellulose, calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc, silica
  • disintegrants e.g., potato starch, sodium starch glycolate
  • wetting agents e.g., sodium lauryl sulphate
  • the pharmaceutical composition can be administered with a physiologically acceptable carrier to a patient, as described herein.
  • pharmaceutically acceptable means approved by a regulatory agency or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium ion, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can be in the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin.
  • Such compositions will contain a therapeutically effective amount of the aforementioned compounds, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • Liquid preparations for oral administration can be in the form of, for example, solutions, syrups, or suspensions, or can be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparation can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol, syrup, cellulose derivatives, hydrogenated edible fats), emulsifying agents (e.g., lecithin, acacia), non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, fractionated vegetable oils), preservatives (e.g., methyl or propyl-p-hydroxycarbonates, soric acids).
  • the preparations can also contain buffer salts, flavouring, coloring and sweetening agents as deemed appropriate.
  • Preparations for oral administration can be suitably formulated to give controlled release of a compound of Formula (I).
  • a compound of Formula (I) of the present invention is conveniently delivered in the form of an aerosol spray presentation from a pressurised pack or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit can be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of, for example, gelatine, for use in an inhaler or insufflator can be formulated containing a powder mix of a compound of Formula (I) and a suitable powder base such as lactose or starch.
  • a compound of Formula (I) of the present invention can be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.
  • Site of injections include intra-venous, intra-peritoneal or sub-cutaneous.
  • Formulations for injection can be presented in units dosage form (e.g., in phial, in multi-dose container), and with an added preservative.
  • a compound of Formula (I) of the present invention can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, or dispersing agents.
  • the agent can be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.
  • compositions for intravenous administration are solutions in sterile isotonic ciLj ⁇ UULi UUi i Ur. VV Mcirfci ⁇ ⁇ ⁇ ', ⁇ UUTilpU iLiUii Uai i cUSU iiivJiUU ⁇ ci owiUiJiiiZ.ii iy agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry iyophilised powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration.
  • a compound of Formula (I) of the present invention can be formulated for transdermal administration.
  • Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
  • the active ingredients When formulated as a ointment, the active ingredients will typically be combined with either a paraffinic or a water- miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base.
  • transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.
  • the compounds of this invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
  • composition of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • a compound of Formula (I) of the present invention can also, if desired, be presented in a pack, or dispenser device which cancontain one or more unit dosage forms containing the said agent.
  • the pack can for example comprise metal or plastic foil, such as blister pack.
  • the pack or dispenser device can be accompanied with instruction for administration.
  • a compound of Formula (I) of the present invention can be administered as sole active agent or can be adminstered in combination with other agents.
  • agents include non-steroidal anti-inflammatory drug (NSAIDS) such as celecoxib, rofecoxib, cimicoxib, etoricoxib, lumiracoxib, valdecoxib, deracoxib, N-(2- cyclohexyloxynitrophenyl)methane sulphonamide, COX189, ABT963, JTE-522, GW- 406381 , LAS-34475, CS-706, PAC-10649, SVT-2016, GW-644784, tenidap, acetylsalicylic acid (aspirin), amoxiprin, benoriiate, choline magnesium salicylate, diflunisal, urgencylamine, methyl salicylate, magnesium salicylate, salicyl salicylate (salsalatee), diclofenac, aceclofenac
  • a compound of Formula (I) of the present invention can be combined with agents such as TNF-a inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and D2E7) and TNF receptor immunoglobulin molecules (such as Enbrel), low dose methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d- penicillamine, auranofin or parenteral or oral gold.
  • TNF-a inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and D2E7) and TNF receptor immunoglobulin molecules (such as Enbrel), low dose methotrexate, lefunomide; ciclesonide; hydroxychloroquine, d- penicillamine, auranofin or parenteral or oral gold.
  • a compound of Formula (I) of the present invention can also be administered in combination with an inhibitor of proTNFalpha convertase enzyme (TACE) such as 3- Amino-N-hvdroxv-a-i2-methvlDroDvlV3-r4-ri2-methvl-4-auinolinvnmethoxvlDhenvll-2- oxo-1 -pyrrolidineacetamide, 2(S),3(S)-Piperidinedicarboxamide, N3-hydroxy-1 - ⁇
  • TACE proTNFalpha convertase enzyme
  • Thiomorpholinecarboxamide 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2- dimethyl, 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-, 2-(2-methyipropyi)-2-(methyisulfonyl)hydrazide, (2R,3S,5E), 2-
  • Piperidinecarboxamide N,5-dihydroxy-1 -[[4-(1 - naphthalenylmethoxy)phenyl]sulfonyl]-, (2R.5R), Pentanamide, 3- (formylhydroxyamino)-4-methyl-2-(2-methylpropyl)-N-[(1 S,2S)-2-methyl-1 -[(2- pyridinylamino)carbonyl]butyl]-, (2R.3S), 2-Propenamide, N-hydroxy-3-[3-[[(4- methoxyphenyl)sulfonyl](1 -methylethyl)amino]phenyl]-3-(3-pyridinyl)-, (2E), Benzamide, N-(2,4-dioxo-1 ,3,7-triazaspiro[4.4]non-9-yl)-4-[(2-methyl-4- quinolinyl)methoxy], Benzamide, N-[(
  • TACE inhibitors are described in WO 99/18074, WO 99/65867, U.S. Pat. No. 6,225,31 1 , WO 00/00465, WO 00/09485, WO 98/38179, WO 02/18326, WO 02/096426, WO 03/079986, WO 03/055856, WO 03/053941 , WO 03/040103, WO 03/031431 , WO 03/024899, WO 03/016248, WO 04/096206, WO 04/033632, WO 04/108086, WO 04/043349, WO 04/032846, WO 04/012663, WO 04/006925, WO 07/016597.
  • a compound of Formula (I) of the present invention can also be administered in combination with a corticosteroid such as budesonide, corticosterone, Cortisol, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate (doca), aldosterone.
  • a corticosteroid such as budesonide, corticosterone, Cortisol, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate (doca), aldosterone.
  • a compound of Formula (I) of the present invention can further be administered in combination with a receptor agonist such as formoterol, salbutamol (albuterol), levalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, salmeterol, bambuterol, clenbuterol.
  • a receptor agonist such as formoterol, salbutamol (albuterol), levalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, salmeterol, bambuterol, clenbuterol.
  • a compound of Formula (I) of the present invention can further be administered in combination with an antidepressant drug such as sertraline, escitalopram, fluoxetine, bupropion, paroxetine, venlafaxine, trazodone, am!triptyl!ne, citaiopram, duloxetine, mirtazapine, nortriptyline, imipramine, lithium.
  • an antidepressant drug such as sertraline, escitalopram, fluoxetine, bupropion, paroxetine, venlafaxine, trazodone, am!triptyl!ne, citaiopram, duloxetine, mirtazapine, nortriptyline, imipramine, lithium.
  • a compound of Formula (I) of the present invention can further be administered in combination with an antipsychotic drug such as chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine, levomepromazine, promethazine, chlorprothixene, flupenthixol, thiothixene, zuclopenthixol, haloperidol, droperidol, pimozide, melperone, benperidol, triperidol, clozapine , olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, paliperidone , bifeprunox, aripiprazole.
  • an antipsychotic drug such as chlorpromazine, fluphenazine, perphenazine, prochlorperazine,
  • a compound of Formula (I) of the present invention can also be administered in combination with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist, for example, zileuton; ABT- 761 ; fenieuton; tepoxalin; nicaraven; VIA-2291 ; etalocib; ketoprofen, Abt-79175; Abt- 85761 ; N-(5-substituted) thiophene-2-alkylsulfonamides; TDT-070; licofelone; PEP- 03; tenoxicam; 2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB- 210661 ; pyridinyl-substituted 2- cyanonaphthalene compounds such as L-739-010;
  • a compound of Formula (I) of the present invention can be administered in combination with a receptor antagonists for leukotrienes LTB4, LTC4, LTD4, and LTE, for example, phenothiazin-3-ones such as L-651 ,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontezolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, praniukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195; masilukast.
  • a receptor antagonists for leukotrienes LTB4, LTC4, LTD4, and LTE for example, phenothiazin-3-ones such as L-651 ,392; amidino compounds such as C
  • a compound of Formula (I) of the present invention can also be administered in combination with a PDE4 inhibitor includina inhibitors of the isoform PDE4D.
  • a compound of Formula (I) of the present invention can further be administered in combination with with a gastroprotective H 2 receptor antagonist.
  • a compound of Formula (I) of the present invention can yet further be administered in combination with an a1 - and a2-adrenoceptor agonist vasoconstrictor sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.
  • an a1 - and a2-adrenoceptor agonist vasoconstrictor sympathomimetic agent including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydroch
  • a compound of Formula (I) of the present invention can be administered in combination with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine
  • anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine
  • the present invention still further relates to the combination of a compound of the invention together with a ⁇ - to 4 -adrenoceptor agonists including metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscar
  • a compound of Formula (I) of the present invention can be administered in combination with an insulin-like growth factor type I (IGF-1 ) mimetic.
  • IGF-1 insulin-like growth factor type I
  • a compound of Formula (I) of the present invention can be administered in combination with an inhaled glucocorticoid with reduced systemic side effects, including, prednisone, prednisolone, fluniso!ide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone r ⁇ .
  • a compound of Formula (I) of the present invention can be administered in combination with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B-i- and B 2 -receptor antagonists; j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, e.g., allopurinol; (I) uricosuric agents, e.
  • g., probenecid, sulfinpyrazone, and benzbromarone (m) growth hormone secretagogues; (n) transforming growth factor (TGFP); (o) platelet- derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor (GM-CSF); (r) capsaicin cream; (s) Tachykinin NKi and NK 3 receptor antagonists such as NKP-608C; SB-233412 (talnetant); and D-4418; and (t) elastase inhibitors such as UT-77 and ZD-0892.
  • TGFP transforming growth factor
  • PDGF platelet- derived growth factor
  • bFGF fibroblast growth factor
  • bFGF basic fibroblast growth factor
  • GM-CSF granulocyte macrophage colony stimulating factor
  • capsaicin cream (s) Tachy
  • a compound of Formula (I) of the present invention can be administered in combination with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1 ), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-1 1 ).
  • MMPs matrix metalloproteases
  • a compound of Formula (I) of the present invention can be administered in combination with anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and farnesyl transferase inhibitors, VEGF inhibitors, COX-2 inhibitors and antimetabolites such as methotrexate antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine.
  • anticancer agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and farnesyl transferase inhibitors, VEGF inhibitors, COX-2 inhibitors and antimetabolites such as methotrexate antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and
  • a compound of Formula (I) of the present invention can be administered in combination with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antisepsis compounds such as Valant.
  • antiviral agents such as Viracept, AZT, aciclovir and famciclovir
  • antisepsis compounds such as Valant.
  • a compound of Formula (!) of the present invention can be administered in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as stating, fibrates, beta-blockers, ACE inhibitors, Angiotensin-
  • a compound of Formula (I) of the present invention can be administered in combination with CNS agents such as antidepressants (such as sertraline), antiparkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and anti-Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.
  • CNS agents such as antidepressants (such as sertraline), antiparkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitor
  • a compound of Formula (I) of the present invention can be administered in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.
  • osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax
  • immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.
  • Figure 1 Analgesic and Anti-inflammatory Effects in a model of pain and inflammation ( * ** p ⁇ 0.001 ).
  • Inhibition of P2X7R activity by the compounds of the present invention is assessed by measuring calcium influx in Hek293 cells (ECACC No. 85120602) which have been stably transfected with a cDNA for the human P2X7R.
  • the Hek293 cells are human embryo kidney cells that do not express endogenous P2X7R (Surprenant et al. (1996) Science 272:735-738). Hek293 cells expressing P2X7R were generated by lipofectamine transfection of the human P2X7R cDNA (Genbank accession number BC01 1913) under the control of the human cytomegalovirus immediate-early (CMV) promoter and inserted into the pcDNA3.1 vector (Invitrogen).
  • CMV cytomegalovirus immediate-early
  • DMEM Dulbecco's modified eagles medium
  • FEM heat- inactivated foetal calf serum (10% v/v)
  • 2 mM L-glutamine 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 750 pg/ml Geneticin G418 (GibcoBRL/lnvitrogen).
  • the cells were incubated in 50 ⁇ of assay buffer containing 100 ⁇ Fluo-4 AM fluorescent dye per well for 1 hour at room temperature.
  • the assay buffer containing the Fluo-4 AM fluorescent dye was then removed, the cells were washed once with assay buffer (without Fluo-4 AM), 100 ⁇ of assay buffer (without Fluo-4 AM) containing the test compounds was then added per well.
  • the analgesic and anti-inflammatory therapeutic benefits of the compounds of the present invention were assessed using a carrageenan-induced paw edema model of inflammation.
  • the development of pain in this model is a biphasic phenomenon (Beena et al. (2008) Indian J Physiol Pharmacol 52: 178-182).
  • the early phase is caused by a release of histamine and serotonin causing vasodialation and increased permeability of capillaries resulting in an increase in vascular permeability.
  • the late phase is characterised by infiltrate of leucocytes due to the release of bradykinin, prostaglandins, protease and lysosomal enzymes which regulate the process of adhesion of molecules (Higgs et al.
  • Carrageenan-induced paw edema model is one of the most reliable method to screen anti-inflammatory agents and analgesics.
  • Example 7 The compound disclosed in Example 7 was prepared in 5% dimethyl sulfoxide (DMSO), 25% triethylene glycol (TEG), and 70% (2-hydroxypropy!-beta-cyc!odextrin ( ⁇ - ⁇ -CD) and injected intraperitonea!ly 1 .5 hours after carrageenan challenge. Control treated animals were injected intraperitoneally with vehicle (5% DMSO, 25% TEG, 70% ⁇ - ⁇ -CD).
  • DMSO dimethyl sulfoxide
  • TEG triethylene glycol
  • ⁇ - ⁇ -CD 2-hydroxypropy!-beta-cyc!odextrin
  • Mean Difference of PWL PWL for Left hind paw (Contralateral) - PWL for Right Hind paw (Ipsilateral). A decrease in mean difference of withdrawal latency in compound treated animals as compared to control vehicle treated animals is considered as an analgesic effect of the treatment and calculated as percentage inhibition.
  • Results are illustrated in Figure 1 .
  • a statistically significant (p ⁇ 0.001 ) reduction of ⁇ 42% in paw withdrawal latency in response to the heat stimulus was observed after administration of 50 mg/kg of the compound when compared to vehicle treated animals. This result supports the analgesic use of the compounds of the present invention for the treatment of pain.
  • a statistically significant (p ⁇ 0.001 ) reduction of 47% in carrageenan induced paw edema was observed after administration of 50 mg/kg of the compound when compared to vehicle treated animals. This result supports the anti-inflammatory use of the compounds of the present invention for the treatment of inflammatory diseases.

Abstract

La présente invention concerne de nouveaux antagonistes de P2X7R qui sont des composés indole-3 carboxamide et azaindole-3 carboxamide, des compositions pharmaceutiques les comprenant et leur utilisation pour le traitement thérapeutique ou prophylactique de maladies à médiation par une activité de P2X7R.
PCT/EP2012/059693 2011-05-27 2012-05-24 Nouveaux antagonistes de p2x7r et leur utilisation WO2012163792A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161491019P 2011-05-27 2011-05-27
EP11167815 2011-05-27
EP11167815.7 2011-05-27
US61/491,019 2011-05-27

Publications (1)

Publication Number Publication Date
WO2012163792A1 true WO2012163792A1 (fr) 2012-12-06

Family

ID=47258393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/059693 WO2012163792A1 (fr) 2011-05-27 2012-05-24 Nouveaux antagonistes de p2x7r et leur utilisation

Country Status (1)

Country Link
WO (1) WO2012163792A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103420951A (zh) * 2013-09-03 2013-12-04 天津全和诚科技有限责任公司 一种合成氧杂环丁烷-3-甲醛的方法
JP2016511252A (ja) * 2013-03-01 2016-04-14 バイエル・ファルマ・アクティエンゲゼルシャフト 置換イミダゾピリダジン
US20160168090A1 (en) * 2014-12-15 2016-06-16 Merck Patent Gmbh Novel indole derivatives and their use in neurodegenerative diseases
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist

Citations (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038179A1 (fr) 1997-02-26 1998-09-03 Glaxo Group Limited Derives d'hydroxamate utilises comme inhibiteurs de metalloprotease
WO1999018074A1 (fr) 1997-10-03 1999-04-15 Britol-Myers Squibb Pharma Company Inhibiteurs de metalloprotease a base de lactame
WO1999029660A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Derives d'adamantane
WO1999029661A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Derives d'adamantane
WO1999029686A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Nouveaux composes
WO1999065867A1 (fr) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
WO2000000465A1 (fr) 1998-06-26 2000-01-06 F. Hoffmann-La Roche Ag Derives d'hydrazine
WO2000009485A1 (fr) 1998-08-12 2000-02-24 Pfizer Products Inc. Derives d'acide hydroxamique de pipecolate hydroxy
WO2000061569A1 (fr) 1999-04-09 2000-10-19 Astrazeneca Ab Derives d'adamantane
WO2000071529A1 (fr) 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
WO2001042194A1 (fr) 1999-12-09 2001-06-14 Astrazeneca Ab Derives d'adamantane
WO2001044213A1 (fr) 1999-12-17 2001-06-21 Astrazeneca Ab Nouveaux antagonistes des recepteurs p2x7 utiles dans le traitement de maladies inflammatoires, immunitaires ou cardiovasculaires
WO2001044170A1 (fr) 1999-12-17 2001-06-21 Astrazeneca Ab Derives d'adamantane
WO2001046200A1 (fr) 1999-12-22 2001-06-28 Astrazeneca Ab Nouveaux derives de piperidine et de piperazine
WO2001094338A1 (fr) 2000-06-07 2001-12-13 Astrazeneca Ab Derives d'admantane
WO2002018326A1 (fr) 2000-08-31 2002-03-07 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'acide propenohydroxamique
WO2002096426A1 (fr) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Derives d'hydantoine utilises comme inhibiteurs des metalloproteinases matricielles
WO2003016248A2 (fr) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Hydroxamates bicycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion du tnf-$g(a) (tace)
WO2003024899A2 (fr) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
WO2003031431A1 (fr) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Derives de sulfone cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
WO2003040103A1 (fr) 2001-11-02 2003-05-15 Bristol-Myers Squibb Company Derives $g(b)-sulfone utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion de tnf-$g(a) (tace)
WO2003042191A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Benzamide et heteroarylamide utilises comme antagonistes du recepteur p2x7
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
WO2003041707A1 (fr) 2001-11-16 2003-05-22 Astrazeneca Ab Derives de n-adamantylmethyle et intermediaires utilises dans des compositions pharmaceutiques et leurs procedes de preparation
WO2003047515A2 (fr) 2001-11-30 2003-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes du recepteur p2x7
WO2003053941A2 (fr) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Derives de l'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-alpha (tace) et/ou de metalloproteases matricielles
WO2003055856A2 (fr) 2001-10-17 2003-07-10 Bristol-Myers Squibb Company Derives bicycliques de lactame utilises en tant qu'inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion du tnf-alpha (tace)
WO2003059353A1 (fr) 2001-12-21 2003-07-24 King Pharmaceuticals Research And Development, Inc. Derives de tyrosyle et leur utilisation comme modulateurs du recepteur p2x7
WO2003079986A2 (fr) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Derives d'uracile utilises en tant qu'inhibiteurs de l'enzyme tnf-alpha convertase (tace) et metalloproteases matricielles
WO2003080579A1 (fr) 2002-03-25 2003-10-02 Astrazeneca Ab Nouveaux derives d'adamantane
WO2004006925A1 (fr) 2002-07-13 2004-01-22 Astrazeneca Ab N-sulfonylpiperidines utilises comme inhibiteurs de metalloproteinase (tace) (enzyme de conversion du facteur de necrose tumorale $g(a))
WO2004012663A2 (fr) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Derives d'yhydantoine utilises comme inhibiteurs de metalloproteases maticielles et/ou d'enzyme de conversion de tnf-alpha
WO2004032846A2 (fr) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
WO2004033632A2 (fr) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
WO2004043349A2 (fr) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Derives d'isoxazoline comme inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion de tnf-$g(a)
WO2004058731A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur p2x7
WO2004058270A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide utilises comme inhibiteurs de p2x7 pour le traitement de maladies inflammatoires
WO2004074224A1 (fr) 2003-02-21 2004-09-02 Astrazeneca Ab Derives d'adamantane, procedes pour les preparer et compositions pharmaceutiques les contenant
WO2004096206A2 (fr) 2003-04-25 2004-11-11 Pharmacia Corporation Combinaison therapeutique d'un inhibiteur de cox-2 et d'un inhibiteur de tace
WO2004099146A1 (fr) 2003-05-12 2004-11-18 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur p2x7
WO2004106305A1 (fr) 2003-06-02 2004-12-09 Astrazeneca Ab Nouveaux comoses
WO2004108086A2 (fr) 2003-06-05 2004-12-16 Bristol-Myers Squibb Company Derives d'hydantoine en tant qu'inhibiteurs de l'enzyme de conversion du facteur ?lpha de necrose tumorale (tace)
WO2005009968A1 (fr) 2003-07-28 2005-02-03 Astrazeneca Ab Derives de la quinoline et leur utilisation en therapie
WO2005014555A1 (fr) 2003-07-21 2005-02-17 Aventis Pharmaceuticals Inc. 4,5-dihydro-imidazole utilise comme antagonistes des canaux ioniques p2x7
WO2005014529A1 (fr) 2003-08-08 2005-02-17 Astrazeneca Ab Derives de 2-adamantyle en tant qu'antagonistes du recepteur p2x7
WO2005019182A1 (fr) 2003-08-20 2005-03-03 Bayer Healthcare Ag Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
WO2005039590A1 (fr) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Compositions non-nucleotidiques et procede de traitement de la douleur
WO2005111003A1 (fr) 2004-04-29 2005-11-24 Abbott Laboratories Analogues d’amino-tétrazoles et méthodes d’utilisation
WO2006003500A1 (fr) 2004-06-29 2006-01-12 Pfizer Products Inc. Procedes permettant de preparer des derives de 5-[4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h-[1,2,4]triazin-2-yl]-benzamides par deprotection des precurseurs proteges par hydroxyle
WO2006003513A1 (fr) 2004-06-29 2006-01-12 Pfizer Products Inc. Procede de preparation de derives de 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4-triazin-2-yl-benzamide aant une activite inhibant p2x7 par reaction du derive non substitue en position 4 de triazine avec un oxyrane en presence d'un acide de lewis
WO2006017406A1 (fr) 2004-08-02 2006-02-16 Abbott Laboratories Cyanoamidines antagonistes de p2x7 pour le traitement de la douleur
WO2006025783A1 (fr) 2004-08-30 2006-03-09 Astrazeneca Ab Derives d'adamantyl utilises comme antagonistes du recepteur p2x7
WO2006059945A1 (fr) 2004-11-30 2006-06-08 Astrazeneca Ab Nouveaux composes
WO2006067444A1 (fr) 2004-12-24 2006-06-29 Astrazeneca Ab Dérivés d'amide
WO2006080884A1 (fr) 2005-01-27 2006-08-03 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
WO2006086229A1 (fr) 2005-02-08 2006-08-17 Abbott Laboratories Utilisation d'antagonistes selectifs du recepteur p2x7
WO2006102610A2 (fr) 2005-03-24 2006-09-28 Renovis, Inc. Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2006110516A1 (fr) 2005-04-11 2006-10-19 Abbott Laboratories Antagonistes de l'acylhydrazide p2x7 et leurs utilisations
WO2006136004A1 (fr) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition des voies dependantes de p2x7 mediees par l'atp au moyen de pyridoxal-5-phosphate et de composes associes a la vitamine b6
WO2007016597A2 (fr) 2005-07-29 2007-02-08 The Regents Of The University Of California Ciblage de secretion de facteur de croissance dependant d'enzyme de conversion de tnf-alpha (tace) dans une therapie anticancereuse
WO2007025366A1 (fr) 2005-08-29 2007-03-08 Irma Bernatchez-Lemaire Utilisation de composes histogranine et du type histogranine comme inhibiteurs de la fonction du recepteur p2x7 et comme agents anti-arthritiques
WO2007028022A2 (fr) 2005-09-01 2007-03-08 Renovis, Inc. Nouveaux composes servant de modulateurs de p2x7 et leurs utilisations
WO2007056046A1 (fr) 2005-11-07 2007-05-18 Abbott Laboratories Antagonistes des recepteurs p2x7 et methodes d'utilisation
WO2007056091A2 (fr) 2005-11-09 2007-05-18 Abbott Laboratories Antagonistes des recepteurs p2x7 et utilisations associees
WO2007109182A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2007109172A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109160A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2007141267A1 (fr) 2006-06-06 2007-12-13 Glaxo Group Limited Dérivés de n- (phénylméthyl) -2- (1h-pyraz0l-4-yl) acétamide utilisés comme antagonistes fp2x7 pour le traitement de la douleur, de l'inflammation et de la neurodégénérescence
WO2007141269A1 (fr) 2006-06-06 2007-12-13 Glaxo Group Limited Nouveaux antagonistes de récepteurs et leurs procédés d'utilisation
WO2008005368A2 (fr) 2006-06-30 2008-01-10 Abbott Laboratories Pipérazines en tant qu'antagonistes de p2x7
WO2008003697A1 (fr) 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitués tenant lieu d'antagonistes du récepteur p2x7 et procédés d'utilisation
WO2008013494A1 (fr) 2006-07-27 2008-01-31 Astrazeneca Ab DÉRIVÉS DE QUINOLINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7 ET LEUR UTILISATION DANS LE TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE, L'OSTÉOARTHRITE, COPD et IBD
WO2008119825A2 (fr) 2007-04-03 2008-10-09 Glaxo Group Limited Dérivés imidazolidine carboxamide comme modulateurs de p2x7
WO2008124153A1 (fr) 2007-04-10 2008-10-16 H. Lundbeck A/S Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
WO2008125600A2 (fr) 2007-04-11 2008-10-23 Glaxo Group Limited Dérivés de pyrazole utilisés comme modulateurs de p2x7
WO2008138876A1 (fr) 2007-05-10 2008-11-20 Glaxo Group Limited Dérivés du pyrazole utilisés comme modulateurs de p2x7
WO2009019503A2 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Nouvelle utilisation 921
WO2009023623A1 (fr) * 2007-08-10 2009-02-19 H, Lundbeck A/S Analogues d'hétéroarylamides
WO2009053459A1 (fr) 2007-10-26 2009-04-30 Glaxo Group Limited Dérivés de 4-benzoyl-1-substitué-pipérazin-2-one comme modulateurs de p2x7
WO2009070116A1 (fr) 2007-11-30 2009-06-04 Astrazeneca Ab Dérivé de quinoléine agissant comme antagoniste du récepteur p2x7
WO2009077559A2 (fr) 2007-12-18 2009-06-25 Glaxo Group Limited Dérivés de 5-oxo-3-pyrrolidinecarboxamide utilisés comme modulateurs de p2x7
WO2009118175A1 (fr) 2008-03-25 2009-10-01 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2009132000A1 (fr) 2008-04-22 2009-10-29 Janssen Pharmaceutica Nv Antagonistes de p2x7 substitués par une quinoline ou isoquinoline
WO2010118921A1 (fr) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2010125103A1 (fr) 2009-04-29 2010-11-04 Glaxo Group Limited Dérivés de dicétopipérazine comme modulateurs de p2x7

Patent Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038179A1 (fr) 1997-02-26 1998-09-03 Glaxo Group Limited Derives d'hydroxamate utilises comme inhibiteurs de metalloprotease
WO1999018074A1 (fr) 1997-10-03 1999-04-15 Britol-Myers Squibb Pharma Company Inhibiteurs de metalloprotease a base de lactame
WO1999029660A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Derives d'adamantane
WO1999029661A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Derives d'adamantane
WO1999029686A1 (fr) 1997-12-05 1999-06-17 Astrazeneca Uk Limited Nouveaux composes
WO1999065867A1 (fr) 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
WO2000000465A1 (fr) 1998-06-26 2000-01-06 F. Hoffmann-La Roche Ag Derives d'hydrazine
WO2000009485A1 (fr) 1998-08-12 2000-02-24 Pfizer Products Inc. Derives d'acide hydroxamique de pipecolate hydroxy
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
WO2000061569A1 (fr) 1999-04-09 2000-10-19 Astrazeneca Ab Derives d'adamantane
WO2000071529A1 (fr) 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
WO2001042194A1 (fr) 1999-12-09 2001-06-14 Astrazeneca Ab Derives d'adamantane
WO2001044213A1 (fr) 1999-12-17 2001-06-21 Astrazeneca Ab Nouveaux antagonistes des recepteurs p2x7 utiles dans le traitement de maladies inflammatoires, immunitaires ou cardiovasculaires
WO2001044170A1 (fr) 1999-12-17 2001-06-21 Astrazeneca Ab Derives d'adamantane
WO2001046200A1 (fr) 1999-12-22 2001-06-28 Astrazeneca Ab Nouveaux derives de piperidine et de piperazine
WO2001094338A1 (fr) 2000-06-07 2001-12-13 Astrazeneca Ab Derives d'admantane
WO2002018326A1 (fr) 2000-08-31 2002-03-07 Wakunaga Pharmaceutical Co., Ltd. Nouveaux derives d'acide propenohydroxamique
WO2002096426A1 (fr) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Derives d'hydantoine utilises comme inhibiteurs des metalloproteinases matricielles
WO2003016248A2 (fr) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Hydroxamates bicycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion du tnf-$g(a) (tace)
WO2003024899A2 (fr) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
WO2003031431A1 (fr) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Derives de sulfone cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
WO2003055856A2 (fr) 2001-10-17 2003-07-10 Bristol-Myers Squibb Company Derives bicycliques de lactame utilises en tant qu'inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion du tnf-alpha (tace)
WO2003040103A1 (fr) 2001-11-02 2003-05-15 Bristol-Myers Squibb Company Derives $g(b)-sulfone utilises comme inhibiteurs de metalloproteinases matricielles et/ou enzyme de conversion de tnf-$g(a) (tace)
WO2003042191A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Benzamide et heteroarylamide utilises comme antagonistes du recepteur p2x7
WO2003042190A1 (fr) 2001-11-12 2003-05-22 Pfizer Products Inc. Derives de n-adamantylalkyle benzamide en tant qu'antagonistes du recepteur p2x7
WO2003041707A1 (fr) 2001-11-16 2003-05-22 Astrazeneca Ab Derives de n-adamantylmethyle et intermediaires utilises dans des compositions pharmaceutiques et leurs procedes de preparation
WO2003047515A2 (fr) 2001-11-30 2003-06-12 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes du recepteur p2x7
WO2003053941A2 (fr) 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Derives de l'acide barbiturique utilises comme inhibiteurs de l'enzyme de conversion du tnf-alpha (tace) et/ou de metalloproteases matricielles
WO2003059353A1 (fr) 2001-12-21 2003-07-24 King Pharmaceuticals Research And Development, Inc. Derives de tyrosyle et leur utilisation comme modulateurs du recepteur p2x7
WO2003079986A2 (fr) 2002-03-18 2003-10-02 Bristol-Myers Squibb Company Derives d'uracile utilises en tant qu'inhibiteurs de l'enzyme tnf-alpha convertase (tace) et metalloproteases matricielles
WO2003080579A1 (fr) 2002-03-25 2003-10-02 Astrazeneca Ab Nouveaux derives d'adamantane
WO2004006925A1 (fr) 2002-07-13 2004-01-22 Astrazeneca Ab N-sulfonylpiperidines utilises comme inhibiteurs de metalloproteinase (tace) (enzyme de conversion du facteur de necrose tumorale $g(a))
WO2004012663A2 (fr) 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Derives d'yhydantoine utilises comme inhibiteurs de metalloproteases maticielles et/ou d'enzyme de conversion de tnf-alpha
WO2004033632A2 (fr) 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
WO2004032846A2 (fr) 2002-10-07 2004-04-22 Bristol-Myers Squibb Company Derives de la triazolone et de la triazolethione, inhibiteurs des metalloproteinases de matrices et/ou de l'enzyme de conversion du tnf$g(a)
WO2004043349A2 (fr) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Derives d'isoxazoline comme inhibiteurs de metalloproteases matricielles et/ou d'enzyme de conversion de tnf-$g(a)
WO2004058731A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur p2x7
WO2004058270A1 (fr) 2002-12-31 2004-07-15 Pfizer Products Inc. Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazin-2-yl)-benzamide utilises comme inhibiteurs de p2x7 pour le traitement de maladies inflammatoires
WO2004074224A1 (fr) 2003-02-21 2004-09-02 Astrazeneca Ab Derives d'adamantane, procedes pour les preparer et compositions pharmaceutiques les contenant
WO2004096206A2 (fr) 2003-04-25 2004-11-11 Pharmacia Corporation Combinaison therapeutique d'un inhibiteur de cox-2 et d'un inhibiteur de tace
WO2004099146A1 (fr) 2003-05-12 2004-11-18 Pfizer Products Inc. Inhibiteurs benzamidiques du recepteur p2x7
WO2004106305A1 (fr) 2003-06-02 2004-12-09 Astrazeneca Ab Nouveaux comoses
WO2004108086A2 (fr) 2003-06-05 2004-12-16 Bristol-Myers Squibb Company Derives d'hydantoine en tant qu'inhibiteurs de l'enzyme de conversion du facteur ?lpha de necrose tumorale (tace)
WO2005014555A1 (fr) 2003-07-21 2005-02-17 Aventis Pharmaceuticals Inc. 4,5-dihydro-imidazole utilise comme antagonistes des canaux ioniques p2x7
WO2005009968A1 (fr) 2003-07-28 2005-02-03 Astrazeneca Ab Derives de la quinoline et leur utilisation en therapie
WO2005014529A1 (fr) 2003-08-08 2005-02-17 Astrazeneca Ab Derives de 2-adamantyle en tant qu'antagonistes du recepteur p2x7
WO2005019182A1 (fr) 2003-08-20 2005-03-03 Bayer Healthcare Ag Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
WO2005039590A1 (fr) 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Compositions non-nucleotidiques et procede de traitement de la douleur
WO2005111003A1 (fr) 2004-04-29 2005-11-24 Abbott Laboratories Analogues d’amino-tétrazoles et méthodes d’utilisation
WO2006003500A1 (fr) 2004-06-29 2006-01-12 Pfizer Products Inc. Procedes permettant de preparer des derives de 5-[4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h-[1,2,4]triazin-2-yl]-benzamides par deprotection des precurseurs proteges par hydroxyle
WO2006003513A1 (fr) 2004-06-29 2006-01-12 Pfizer Products Inc. Procede de preparation de derives de 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4-triazin-2-yl-benzamide aant une activite inhibant p2x7 par reaction du derive non substitue en position 4 de triazine avec un oxyrane en presence d'un acide de lewis
WO2006017406A1 (fr) 2004-08-02 2006-02-16 Abbott Laboratories Cyanoamidines antagonistes de p2x7 pour le traitement de la douleur
WO2006025783A1 (fr) 2004-08-30 2006-03-09 Astrazeneca Ab Derives d'adamantyl utilises comme antagonistes du recepteur p2x7
WO2006059945A1 (fr) 2004-11-30 2006-06-08 Astrazeneca Ab Nouveaux composes
WO2006067444A1 (fr) 2004-12-24 2006-06-29 Astrazeneca Ab Dérivés d'amide
WO2006080884A1 (fr) 2005-01-27 2006-08-03 Astrazeneca Ab Nouveaux composes biaromatiques, inhibiteurs du recepteur p2x7
WO2006086229A1 (fr) 2005-02-08 2006-08-17 Abbott Laboratories Utilisation d'antagonistes selectifs du recepteur p2x7
WO2006102610A2 (fr) 2005-03-24 2006-09-28 Renovis, Inc. Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2006102588A1 (fr) 2005-03-24 2006-09-28 Renovis, Inc. Composes bicycloheteroaryle servant de modulateurs de p2x7 et utilisations de ceux-ci
WO2006110516A1 (fr) 2005-04-11 2006-10-19 Abbott Laboratories Antagonistes de l'acylhydrazide p2x7 et leurs utilisations
WO2006136004A1 (fr) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition des voies dependantes de p2x7 mediees par l'atp au moyen de pyridoxal-5-phosphate et de composes associes a la vitamine b6
WO2007016597A2 (fr) 2005-07-29 2007-02-08 The Regents Of The University Of California Ciblage de secretion de facteur de croissance dependant d'enzyme de conversion de tnf-alpha (tace) dans une therapie anticancereuse
WO2007025366A1 (fr) 2005-08-29 2007-03-08 Irma Bernatchez-Lemaire Utilisation de composes histogranine et du type histogranine comme inhibiteurs de la fonction du recepteur p2x7 et comme agents anti-arthritiques
WO2007028022A2 (fr) 2005-09-01 2007-03-08 Renovis, Inc. Nouveaux composes servant de modulateurs de p2x7 et leurs utilisations
WO2007056046A1 (fr) 2005-11-07 2007-05-18 Abbott Laboratories Antagonistes des recepteurs p2x7 et methodes d'utilisation
WO2007056091A2 (fr) 2005-11-09 2007-05-18 Abbott Laboratories Antagonistes des recepteurs p2x7 et utilisations associees
WO2007109182A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2007109172A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109160A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A2 (fr) 2006-03-16 2007-09-27 Renovis, Inc. Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2007141267A1 (fr) 2006-06-06 2007-12-13 Glaxo Group Limited Dérivés de n- (phénylméthyl) -2- (1h-pyraz0l-4-yl) acétamide utilisés comme antagonistes fp2x7 pour le traitement de la douleur, de l'inflammation et de la neurodégénérescence
WO2007141269A1 (fr) 2006-06-06 2007-12-13 Glaxo Group Limited Nouveaux antagonistes de récepteurs et leurs procédés d'utilisation
WO2008005368A2 (fr) 2006-06-30 2008-01-10 Abbott Laboratories Pipérazines en tant qu'antagonistes de p2x7
WO2008003697A1 (fr) 2006-07-06 2008-01-10 Glaxo Group Limited N-phenylmethyl -5-oxo-proline-2-amides substitués tenant lieu d'antagonistes du récepteur p2x7 et procédés d'utilisation
WO2008013494A1 (fr) 2006-07-27 2008-01-31 Astrazeneca Ab DÉRIVÉS DE QUINOLINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7 ET LEUR UTILISATION DANS LE TRAITEMENT DE LA POLYARTHRITE RHUMATOÏDE, L'OSTÉOARTHRITE, COPD et IBD
WO2008119825A2 (fr) 2007-04-03 2008-10-09 Glaxo Group Limited Dérivés imidazolidine carboxamide comme modulateurs de p2x7
WO2008124153A1 (fr) 2007-04-10 2008-10-16 H. Lundbeck A/S Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
WO2008125600A2 (fr) 2007-04-11 2008-10-23 Glaxo Group Limited Dérivés de pyrazole utilisés comme modulateurs de p2x7
WO2008138876A1 (fr) 2007-05-10 2008-11-20 Glaxo Group Limited Dérivés du pyrazole utilisés comme modulateurs de p2x7
WO2009019503A2 (fr) 2007-08-03 2009-02-12 Astrazeneca Ab Nouvelle utilisation 921
WO2009023623A1 (fr) * 2007-08-10 2009-02-19 H, Lundbeck A/S Analogues d'hétéroarylamides
WO2009053459A1 (fr) 2007-10-26 2009-04-30 Glaxo Group Limited Dérivés de 4-benzoyl-1-substitué-pipérazin-2-one comme modulateurs de p2x7
WO2009070116A1 (fr) 2007-11-30 2009-06-04 Astrazeneca Ab Dérivé de quinoléine agissant comme antagoniste du récepteur p2x7
WO2009077559A2 (fr) 2007-12-18 2009-06-25 Glaxo Group Limited Dérivés de 5-oxo-3-pyrrolidinecarboxamide utilisés comme modulateurs de p2x7
WO2009118175A1 (fr) 2008-03-25 2009-10-01 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2009132000A1 (fr) 2008-04-22 2009-10-29 Janssen Pharmaceutica Nv Antagonistes de p2x7 substitués par une quinoline ou isoquinoline
WO2010118921A1 (fr) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Nouveaux antagonistes de p2x7r et leur utilisation
WO2010125103A1 (fr) 2009-04-29 2010-11-04 Glaxo Group Limited Dérivés de dicétopipérazine comme modulateurs de p2x7

Non-Patent Citations (41)

* Cited by examiner, † Cited by third party
Title
ANDERSON; NEDERGAARD, TRENDS NEUROSCIEN, vol. 29, 2006, pages 257 - 262
ANSEL ET AL.: "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS PUBLISHERS
BARDEN ET AL., AM J MED GENET B, vol. 141, no. B, 2006, pages 374 - 382
BARICORDI ET AL., BLOOD, vol. 87, 1996, pages 682 - 690
BASSO ET AL., BEHAV BRAIN RES, vol. 198, 2009, pages 83 - 90
BEENA ET AL., INDIAN J PHYSIOL PHARMACOL, vol. 52, 2008, pages 178 - 182
CESARO ET AL., AM J PHYSIOL-GASTR L, vol. 299, 2010, pages G32 - 42
CHEN ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 8199 - 8203
CHESSELL ET AL., PAIN, vol. 114, 2005, pages 386 - 396
COLLO ET AL., NEUROPHARMACOL, vol. 36, 1997, pages 1277 - 1283
COLLO ET AL., NEUROPHARMACOLOGY, vol. 36, 1997, pages 1277 - 1283
DAHLQVIST; DIAMANT, ACTA PHYSIOL. SCAND., vol. 34, 1974, pages 368 - 384
DI VIRGILIO ET AL., PURINERGIC SIGNAL, vol. 5, 2009, pages 251 - 256
DI VIRGILIO, CELL DEATH DIFFER., vol. 5, 1998, pages 191 - 199
FALZONI ET AL., J. CLIN. INVEST., vol. 95, 1995, pages 1207 - 1216
FERRARI ET AL., J IMMUNOL, vol. 176, 2006, pages 3877 - 3883
FERRARI ET AL., J. IMMUNOL, vol. 156, 1996, pages 1531 - 1539
GORDON, BIOCHEM. J., vol. 233, 1986, pages 309 - 319
GREENBERG ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 10337 - 10343
GRIFFITHS ET AL., J. IMMOL., vol. 154, 1995, pages 2821 - 2828
HIGGS ET AL., ANN CLIN RES, vol. 16, 1984, pages 287 - 299
HUMPHREYS ET AL., MOL. PHARMACOL., vol. 54, 1998, pages 22 - 32
JIANG ET AL., MOL. PHAMACOL., vol. 58, 2000, pages 82 - 88
MATUTE ET AL., J NEUROSCI, vol. 27, 2007, pages 9525 - 9533
NARCISSE ET AL., GLIA, vol. 49, 2005, pages 245 - 258
NORTH; SURPRENANT, ANNUAL REV. PHARMACOLOGY TOXICOLOGY, vol. 40, 2000, pages 563 - 580
PARVATHENANI ET AL., J BIOL CHEM, vol. 278, 2003, pages 13300 - 13317
PERREGAUX; GABEL, J BIOL CHEM, vol. 269, 1998, pages 15195 - 15203
RACHCHH; JAIN, INDIAN J PHARMACOL, vol. 40, 2008, pages 271 - 275
RASSENDREN ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 5482 - 5486
RESTA ET AL., EUR J NEUROSCI, vol. 25, 2007, pages 2741 - 2754
STEINBERG ET AL., J. BIOL. CHEM., vol. 262, 1987, pages 8884 - 8888
STEINBERG; SILVERSTEIN, J. BIOL. CHEM., vol. 262, 1987, pages 3118 - 3122
SUN, MOL NEUROBIOL, vol. 41, 2010, pages 351 - 355
SURPRENANT ET AL., SCIENCE, vol. 272, 1996, pages 3118 - 3122
SURPRENANT ET AL., SCIENCE, vol. 272, 1996, pages 735 - 738
VIRGINIO ET AL., J. PHYSIOL., vol. 519, 1999, pages 335 - 346
WANG ET AL., NATURE MED, vol. 10, 2004, pages B21 - B27
WILHELM ET AL., NAT MED, vol. 16, 2010, pages 1434 - 1438
WUITSCHIK ET AL., J. MED. CHEM., vol. 53, 2010, pages 3227 - 3246
ZULFKAR ET AL., J PHARM SCI, vol. 22, 2009, pages 287 - 290

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
US9388197B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9388198B2 (en) 2013-01-22 2016-07-12 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
JP2016511252A (ja) * 2013-03-01 2016-04-14 バイエル・ファルマ・アクティエンゲゼルシャフト 置換イミダゾピリダジン
CN103420951A (zh) * 2013-09-03 2013-12-04 天津全和诚科技有限责任公司 一种合成氧杂环丁烷-3-甲醛的方法
US20160168090A1 (en) * 2014-12-15 2016-06-16 Merck Patent Gmbh Novel indole derivatives and their use in neurodegenerative diseases
US10323000B2 (en) * 2014-12-15 2019-06-18 Merck Patent Gmbh Indole derivatives and their use in neurodegenerative diseases
AU2015362700B2 (en) * 2014-12-15 2020-04-16 Merck Patent Gmbh Indole and azaindoles derivatives and their use in neurodegenerative diseases
US10676433B2 (en) 2014-12-15 2020-06-09 Merck Patent Gmbh Indole derivatives and their use in neurodegenerative diseases

Similar Documents

Publication Publication Date Title
US8268861B2 (en) P2X7R antagonists and their use
US8569334B2 (en) P2X7R antagonists and their use
WO2012163792A1 (fr) Nouveaux antagonistes de p2x7r et leur utilisation
AU2006257861A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BRPI0714840A2 (pt) composto, processo para a preparaÇço e uso do mesmo, composiÇço farmacÊutica, processo para a preparaÇço da mesma, e, produto
HRP20050185A2 (en) -3 (sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
CA2655999A1 (fr) Agent de traitement pour la maladie intestinale inflammatoire
WO2012110190A1 (fr) Nouveaux antagonistes p2x7r et leur utilisation
US8815892B2 (en) P2X7R antagonists and their use
WO2012163456A1 (fr) Nouveaux antagonistes de p2x7r et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12729374

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12729374

Country of ref document: EP

Kind code of ref document: A1